GlassScriptPhysician profile
Jonven J Attia
NPI 1780067272
$1,952.18
in general payments reported to CMS, 2019-2025
29 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $456 · 2023: $320 · 2024: $323 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.42 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $209.44 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $202.00 | 2022-2025 | Evenity, Prolia |
| Medtronic, INC. | $195.79 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $153.81 | 2022-2025 | Sogroya, Norditropin |
| Tandem Diabetes Care, INC. | $139.88 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $118.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Recordati_rare_diseases_inc. | $114.10 | 2025 | Isturisa |
| Lilly USA, LLC | $80.93 | 2022-2025 | Mounjaro, Zepbound |
| Ascendis Pharma Endocrinology INC | $66.24 | 2023-2025 | Yorvipath |
| Ibsa Pharma INC. | $65.52 | 2022-2023 | Tirosint, Licart |
| Abbott Laboratories | $56.44 | 2022-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $54.08 | 2024-2025 | Keveyis, Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $46.22 | 2023-2024 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.93 | 2022 | |
| Boston Scientific Corporation | $41.35 | 2024 | Advantage System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $40.95 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $38.86 | 2022 | |
| Horizon Therapeutics Plc | $37.63 | 2022-2023 | Tepezza |
| Zealand Pharma US, INC. | $36.04 | 2021 | |
| Corcept Therapeutics | $32.35 | 2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $25.56 | 2022 | |
| Abbvie INC. | $24.02 | 2024 | |
| Kyowa Kirin, INC. | $23.88 | 2025 | |
| Sequel Med Tech, LLC | $21.19 | 2025 | Twiist |
| Insulet Corporation | $20.93 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $17.36 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.39 | 2023 | |
| Cequr Corporation | $15.12 | 2022 | |
| Bigfoot Biomedical INC | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonven Attia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.